JP2006513208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513208A5 JP2006513208A5 JP2004563592A JP2004563592A JP2006513208A5 JP 2006513208 A5 JP2006513208 A5 JP 2006513208A5 JP 2004563592 A JP2004563592 A JP 2004563592A JP 2004563592 A JP2004563592 A JP 2004563592A JP 2006513208 A5 JP2006513208 A5 JP 2006513208A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- occurrence
- optionally substituted
- nrco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 84
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 48
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- 229910052717 sulfur Inorganic materials 0.000 claims 30
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 19
- 239000001301 oxygen Substances 0.000 claims 19
- 239000011593 sulfur Substances 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- -1 nitro-substituted pyrazole Chemical class 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- 125000001118 alkylidene group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 108010087686 src-Family Kinases Proteins 0.000 claims 2
- 125000003363 1,3,5-triazinyl group Chemical class N1=C(N=CN=C1)* 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CCC*c1nnc(cc2)[n]1nc2SC1CC1 Chemical compound CCC*c1nnc(cc2)[n]1nc2SC1CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43512402P | 2002-12-18 | 2002-12-18 | |
| US60/435,124 | 2002-12-18 | ||
| PCT/US2003/039990 WO2004058769A2 (en) | 2002-12-18 | 2003-12-17 | Triazolopyridazines as protein kinases inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006513208A JP2006513208A (ja) | 2006-04-20 |
| JP2006513208A5 true JP2006513208A5 (https=) | 2007-01-25 |
| JP4817661B2 JP4817661B2 (ja) | 2011-11-16 |
Family
ID=32682164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563592A Expired - Fee Related JP4817661B2 (ja) | 2002-12-18 | 2003-12-17 | プロテインキナーゼインヒビターとしてのトリアゾロピリダジン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7268136B2 (https=) |
| EP (1) | EP1575959B1 (https=) |
| JP (1) | JP4817661B2 (https=) |
| KR (1) | KR101075812B1 (https=) |
| CN (1) | CN100567296C (https=) |
| AT (1) | ATE473980T1 (https=) |
| AU (1) | AU2003297161B8 (https=) |
| CA (1) | CA2510534C (https=) |
| DE (1) | DE60333387D1 (https=) |
| MX (1) | MXPA05006478A (https=) |
| NO (1) | NO20053470L (https=) |
| NZ (1) | NZ541151A (https=) |
| RU (1) | RU2005122484A (https=) |
| WO (1) | WO2004058769A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171062A1 (en) * | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| AU2003272548A1 (en) * | 2002-09-16 | 2004-04-30 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| WO2004090158A1 (ja) * | 2003-04-03 | 2004-10-21 | Oncorex, Inc. | 医薬品 |
| FR2876584B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US8053454B2 (en) | 2005-10-06 | 2011-11-08 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 |
| HUE030390T2 (en) * | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| JP2009538899A (ja) * | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US8481538B2 (en) * | 2006-09-18 | 2013-07-09 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-Met and uses thereof |
| AU2007309149C1 (en) * | 2006-10-23 | 2013-04-04 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| BRPI0718029A2 (pt) * | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| EP2074103A1 (en) | 2007-04-25 | 2009-07-01 | Exelixis, Inc. | 6-phenylpyrimidinones as pim modulators |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
| HRP20151128T1 (hr) | 2007-09-27 | 2015-11-20 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze |
| WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| SG173610A1 (en) * | 2009-02-13 | 2011-09-29 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| US8815918B2 (en) | 2009-04-02 | 2014-08-26 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives |
| PH12012501361A1 (en) * | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| EA025304B1 (ru) | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012098387A1 (en) * | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| PL2678329T3 (pl) | 2011-02-25 | 2016-06-30 | Array Biopharma Inc | Związki triazolopirydyny jako inhibitory kinaz pim |
| WO2012125667A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| JP2014516941A (ja) | 2011-04-29 | 2014-07-17 | アムジェン インコーポレイテッド | Ｐｉｍ阻害剤としての二環式ピリダジン化合物 |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| WO2013004984A1 (en) * | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US9586963B2 (en) * | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
| EP2844660B1 (en) * | 2012-05-02 | 2017-11-01 | Southern Research Institute | Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| CN102938491B (zh) * | 2012-09-28 | 2014-12-10 | 华为终端有限公司 | 天线、组合天线和移动终端 |
| AU2014223990A1 (en) * | 2013-02-28 | 2015-09-10 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
| GB201321745D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| CN109651253B (zh) * | 2017-10-12 | 2022-03-25 | 上海医药工业研究院 | 苯丙烯酸酯衍生物及其作为神经保护药物的应用 |
| CN108498512A (zh) * | 2018-04-22 | 2018-09-07 | 于志国 | 一种治疗心力衰竭的药物组合物及其制备方法和用途 |
| CN109045036B (zh) * | 2018-07-19 | 2020-10-02 | 中山大学 | [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用 |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2153902A1 (de) * | 1971-10-29 | 1973-05-03 | Boehringer Mannheim Gmbh | Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben |
| DE2261693A1 (de) * | 1972-04-01 | 1974-06-20 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| DE2254783A1 (de) * | 1972-04-01 | 1974-05-16 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| DE2215999B2 (de) * | 1972-04-01 | 1977-10-20 | Boehnnger Mannheim GmbH, 6800 Mannheim | 3-(5-nitro-2-imidazolyl)-s-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und arzneimittel |
| PL84022B1 (https=) * | 1972-04-01 | 1976-02-28 | ||
| DE2261735A1 (de) * | 1972-04-01 | 1974-06-20 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| DE2418435A1 (de) * | 1974-04-17 | 1975-10-30 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| FR2668151A1 (fr) * | 1990-10-23 | 1992-04-24 | Rhone Poulenc Agrochimie | Composes a groupe triazolopyridazine leurs preparations et compositions herbicides les contenant. |
| ES2194205T3 (es) * | 1996-07-25 | 2003-11-16 | Merck Sharp & Dohme | Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba. |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| DE10038019A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| WO2002083675A2 (en) * | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| US20050096322A1 (en) * | 2002-03-01 | 2005-05-05 | Susumu Igarashi | Nitrogen-containing heterocyclic compound |
| JP4385620B2 (ja) * | 2002-03-01 | 2009-12-16 | アステラス製薬株式会社 | 含窒素複素環化合物 |
-
2003
- 2003-12-17 WO PCT/US2003/039990 patent/WO2004058769A2/en not_active Ceased
- 2003-12-17 JP JP2004563592A patent/JP4817661B2/ja not_active Expired - Fee Related
- 2003-12-17 NZ NZ541151A patent/NZ541151A/en unknown
- 2003-12-17 CA CA2510534A patent/CA2510534C/en not_active Expired - Fee Related
- 2003-12-17 KR KR1020057011467A patent/KR101075812B1/ko not_active Expired - Fee Related
- 2003-12-17 DE DE60333387T patent/DE60333387D1/de not_active Expired - Lifetime
- 2003-12-17 AU AU2003297161A patent/AU2003297161B8/en not_active Ceased
- 2003-12-17 AT AT03814020T patent/ATE473980T1/de not_active IP Right Cessation
- 2003-12-17 US US10/738,956 patent/US7268136B2/en not_active Expired - Fee Related
- 2003-12-17 RU RU2005122484/04A patent/RU2005122484A/ru not_active Application Discontinuation
- 2003-12-17 EP EP03814020A patent/EP1575959B1/en not_active Expired - Lifetime
- 2003-12-17 MX MXPA05006478A patent/MXPA05006478A/es active IP Right Grant
- 2003-12-17 CN CNB2003801091296A patent/CN100567296C/zh not_active Expired - Fee Related
-
2005
- 2005-07-15 NO NO20053470A patent/NO20053470L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513208A5 (https=) | ||
| CA2510534A1 (en) | Compositions useful as inhibitors of protein kinases | |
| JP6231226B2 (ja) | ピロリジン−２，５−ジオン誘導体、医薬組成物およびｉｄｏ１阻害剤としての使用のための方法 | |
| JP5726190B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| EP1183252B1 (en) | pharmaceutically active compounds | |
| CN102471329B (zh) | 用作治疗肿瘤性或自身免疫性疾病的前药的呋咱并苯并咪唑 | |
| JP6891286B2 (ja) | チューブリン阻害剤 | |
| JP2010510215A5 (https=) | ||
| KR101907631B1 (ko) | 1,5-디페닐-펜타-1,4-디엔-3-온 화합물 | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| EP2723340A1 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| KR20170031786A (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| AU2023417544A1 (en) | Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof | |
| JPH0558894A (ja) | 抗腫瘍剤 | |
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| CA3030232A1 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| CN110437119B (zh) | 一种n-取代含氮杂环衍生物及其制备方法与应用 | |
| JPH0543698B2 (https=) | ||
| CN114605407B (zh) | 一种吲哚喹啉酮类化合物及其合成方法和应用 | |
| JP2015518484A (ja) | ゲラニルゲラニルアセトン類似化合物及びその使用 | |
| KR20230143611A (ko) | 바이사이클릭 고리를 포함하는 tyk2 억제제 화합물 | |
| CN117050066B (zh) | 2-苯并噁唑酮类衍生物及其制备方法和应用 | |
| CN111718350A (zh) | 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用 | |
| WO2023224128A1 (ja) | 線維症の治療又は予防のための医薬組成物 | |
| MX2015000797A (es) | Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular. |